Novel Antiplatelet Therapies

Kim, Luke; Charitakis, Konstantinos; Swaminathan, Rajesh V.; Feldman, Dmitriy N.

doi:10.1007/s11883-011-0216-x

Cited by 8 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New agents such as thrombin receptor antagonists in conjunction with existing agents such as GPIIb/IIIa inhibitors are currently being explored [99]. Although this therapy is effectively utilized to treat coronary artery disease, ischemic stroke and peripheral artery diseases as well as the prevention of future thrombotic events (as is the case in TIA), major adverse clinical events have been observed in a small number of individuals.…”

Section: Par-1 Inhibitorsmentioning

confidence: 99%

Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke

Rooy

Pretorius

2015

Thrombosis Research

View full text Add to dashboard Cite

Section: Par-1 Inhibitorsmentioning

confidence: 99%

Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke

Rooy

Pretorius

2015

Thrombosis Research

View full text Add to dashboard Cite

“…In previous studies, prescription of CYP2C19 pharmacogenetics in patients on clopidogrel treatment was shown to have a benefit in a cost-effectiveness strategy in order to prescribe the most effective antiplatelet drug [21][22][23].…”

Section: Discussionmentioning

confidence: 99%

CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data Warehouse

Maes,

Gosselin,

Triquenot

et al. 2023

Preprint

View full text Add to dashboard Cite

Clopidogrel is one of the most prescribed antiplatelet drugs for cardiovascular diseases prevention. Clopidogrel is a prodrug metabolised by CYP2C19 in active metabolites with anti-aggregant effect. Pharmacogenetic variants such as CYP2C19*2 variant can alter the anti-aggregant effect of clopidogrel leading to a higher risk of cardiovascular disease relapse. The aim of this study was to evaluate the prescription characteristics of CYP2C19 pharmacogenetics in patients on clopidogrel treatment, based on a specific query in a clinical data warehouse. We evaluated the demographics of patients, prescribers, medical indications, CYP2C19 pharmacogenetic tests and therapeutic changes. Neurologists were the main prescribers of CYP2C19 pharmacogenetic tests associated with clopidogrel treatment in a context of suspicion of stroke relapse. Pharmacogenetic tests were mainly prescribed a posteriori to clopidogrel prescription. Clopidogrel pharmacogenetic resistance was associated with the prescription of lysine acetylsalicylate in substitution of clopidogrel. Clear clinical practice guidelines are needed to position CYP2C19 pharmacogenetic testing for patients on clopidogrel treatment.

show abstract

“…In fact, the P2Y 12 receptor is the target for thienopyridine compounds like ticlopidine and clopidogrel which have been used in the treatment of patients at risk for major adverse cardiovascular event (MACE) [14][15][16]. Ticlopidine was first synthesized in 1974 [17], and clopidogrel was its successor [18].…”

Section: +mentioning

confidence: 99%

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Jagroop

2013

Purinergic Signalling

View full text Add to dashboard Cite

Adenosine diphosphate (ADP) plays a pivotal role in platelet activation. Platelet hyperactivity is associated with vascular disease and also has a key role in haemostasis and thrombosis. ADP activates platelets through three purinoceptor subtypes, the G q -coupled P2Y 1 receptor, G icoupled P2Y 12 receptor and P2X 1 ligand-gated cation channel. Platelet ADP purinergic receptors are therefore suitable targets for antiplatelet drugs. Thienopyridines such as clopidogrel and ticlopidine, as well as other ADP receptor antagonists like prasugrel, ticagrelor, cangrelor and elinogrel have demonstrated clinical benefits via the inhibition of the selective purinergic ADP receptor, P2Y 12 . However, they still have limitations in their mode of action and efficacy, like increased risk of bleeding. Thus, the ongoing pursuit to develop newer and more effective antiplatelet agents continues. There is a growing interest in the purinergic antiplatelet properties exhibited by plant extracts. This article considers the following: pomolic acid isolated from Licania pittieri, brazilin isolated from the heartwood of Caesalpinia sappan L, phylligenin isolated from the twigs of Muraltia vulpina , bark oil of Gonystylus velutinus , seed and bark extracts from Aesculus hippocastanum L . and red wine phenolics and catechins isolated from green tea. Moreover, the method used to investigate platelet purinergic receptors should be considered, since using a more sensitive, highresolution platelet sizer can sometimes detect platelet variations when the light transmission method was not able to do so. The exact mechanisms by which these plant extracts work need further investigation. They all however inhibit ADP-induced activation in human platelets. This could explain, at least in part, the protective effect of plant extracts as antiplatelet agents.

show abstract

Novel Antiplatelet Therapies

Cited by 8 publications

References 60 publications

Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke

Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke

CYP2C19 Pharmacogenetics and Clopidogrel Prescription in a University Hospital: A Descriptive Study in a Clinical Data Warehouse

Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists

Contact Info

Product

Resources

About